Amgen Declares $2.38 Dividend for First Quarter of 2025
Amgen (NASDAQ: AMGN) has declared a dividend of $2.38 per share for the first quarter of 2025. This important announcement reflects the company's ongoing commitment to its stockholders. The dividend is set to be distributed on March 7, 2025, to all shareholders registered by the close of business on February 14, 2025.
Company Overview
Founded over four decades ago, Amgen has been at the forefront of biotechnological innovation. The company's mission is to discover, develop, manufacture, and deliver groundbreaking medicines to aid countless patients facing challenging health conditions. With a diverse portfolio, Amgen focuses on combating diseases ranging from cancer and heart disease to rare and connective tissue disorders, exemplifying its commitment to improving health worldwide.
Accolades and Recognitions
In recent years, Amgen has received notable accolades such as being named one of the 'World's Most Innovative Companies' by Fast Company, and it earned recognition as one of 'America's Best Large Employers' by Forbes. These honors emphasize not only the company's innovative approach but also its dedication to fostering a positive workplace environment.
Presence in Major Indices
Amgen holds a significant position in the stock market, being one of the 30 companies included in the Dow Jones Industrial Average. Additionally, it is listed in the Nasdaq-100 Index, which features the largest and most innovative companies listed based on market capitalization. Such prestige solidifies Amgen's role as a key player within the biotechnology landscape.
Innovative Developments Ahead
The journey of innovation continues at Amgen with a strong pipeline of potential new treatments. The company actively engages in research and development for therapies that address various ailments. The combination of advanced technology and human genetic data facilitates a deeper understanding of diseases, allowing Amgen to push the boundaries of medical science.
Commitment to Global Health
Amgen remains dedicated to contributing to global health improvements. The company’s focus on developing effective therapies is paramount as it navigates the complexities of the healthcare system. Collaborations with various stakeholders enhance Amgen’s ability to bring new medicines to market swiftly and efficiently, thereby benefiting patients around the globe.
Outreach and Community Engagement
Engaging with the community is integral to Amgen's operations. The company often participates in outreach programs aimed at educating the public about health and wellness. Supporting initiatives that align with their vision for health equity ensures that Amgen not only contributes to the medical field but also fosters healthier communities.
Frequently Asked Questions
What is the amount of the declared dividend for the first quarter of 2025?
The declared dividend is $2.38 per share, reflecting Amgen's commitment to its stockholders.
When will the dividend be paid?
The dividend will be distributed on March 7, 2025, to shareholders who are registered by February 14, 2025.
How has Amgen been recognized recently?
Amgen was named one of the 'World's Most Innovative Companies' and ranked among 'America's Best Large Employers' in recent accolades.
In which major stock indices is Amgen included?
Amgen is part of the Dow Jones Industrial Average and the Nasdaq-100 Index.
What types of diseases does Amgen focus on treating?
Amgen develops therapies for cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases, among others.
